ABSTRACT. The methylxanthine derivative pentoxifyl-Q~, pulmonary blood flow line (PTF) demonstrates vasodilatory properties in vivo.
Pulmonary hypertension induced by a variety of possible U46,619 for 30 min plus pretreatment and continuous mechanisms characterizes or complicates many neonatal respiinfusion of PTF (n = 5). There was no difference in ratory disorders (1, 2) . For example, phospholipid vasoactive pulmonary or systemic hemodynamic indices between the mediators may induce or exacerbate pulmonary hypertension in three groups at baseline. PVR was significantly elevated the clinical syndrome of persistent pulmonary hypertension of at 15 min and at 2 h in the TNF,-only group. The TNF,-the newborn (3, 4) . Both membrane-derived eicosanoids and induced rise in mean pulmonary artery pressure and PVR polypeptide cytokines can produce acute increases in Ppa in was inhibited by the PTF until 2 h, by which time PVR neonatal experimental animals (5, 6) . However, at present, there was elevated above baseline and was comparable to the is no comprehensive understanding of how combinations of value found in animals treated with only TNF,. PTF pro-various classes of vasoactive mediators interact to initiate or duced no inhibition in the U46,619-induced elevation of sustain elevations in PVR. It is also unclear how the interaction PVR during the 30-min simultaneous treatment. In the of vasoactive substances interferes with pulmonary gas exchange PTF + TNF, group, mean systemic blood pressure declined during induced pulmonary hypertension.
to 50% of baseline value (p < 0.02) by 2 h of age. No We (7) and others (8) have shown that bacterial infusionsignificant decline was noted in mean systemic arterial induced release of TXAl (measured by its metabolite TXB2) pressure of the TNF,-only or the U46,619-treated group. produced both immediate pulmonary hypertension and interferPlasma 6-keto-prostaglandin F,, increased above baseline ence with VA/Q matching. The TX mimetic, U46, 6 19 , also values by 2 h only in the PTF + TNF,-treated group (p < produces immediate increases in PVR in neonatal animals (5, 0.02); no significant change from baseline in thromboxane 9). This model system can serve to test the specific effects of B2 levels was found in any experimental group. We con-putative pulmonary vasodilator agents in a neonatal animal. clude that treatment with PTF transiently inhibited the The polypeptide cytokine TNF, induces multiple pulmonary TNF,-induced elevation in mean pulmonary artery pres-pathophysiologic changes in adult animal models (10) . We have sure and PVR but was associated also with significant shown previously that an acute increase in PVR in neonatal systemic hypotension. PTF failed to counteract elevated piglets can be induced by an i.v. infusion of rhTNF, (6) . The PVR produced by the thromboxane mimetic, U46,619. elevated Ppa was transiently inhibited by pretreatment with the (Pediatr Res 31: 163-169,1992) putative TX synthase inhibitor, dazmegrel. We have also recently demonstrated elevated plasma levels of TNF, beginning after 2 Abbreviations h of i.v. bacterial infusion, suggesting that this substance may participate in maintaining elevated PVR during later phases of PTF, pentoxifylline neonatal sepsis (1 1) . TNF,, tumor necrosis factor-a
The methylxanthine derivative PTF has been shown in vitro rhTNF,, recombinant human tumor necrosis factor-a to inhibit TNF,-induced changes in neutrophil adherence to PVR, pulmonary vascular resistance endothelial cells (12, 13) and has been shown in vivo to protect Ppa, mean pulmonary artery pressure against endotoxin-induced pulmonary vascular injury in both 164 TRUOG ET AL.
20% of that found in GBS-infused animals without PTF treat-plasma samples were found when standard curves run with ment by 4 h (I I). However, there was no difference in plasma eicosanoid-free piglet plasma prepared by charcoal stripping were TXB2 by 4 h and only modest reduction in the PVR of the GBS compared with curves generated from samples not treated with + PTF animals compared with the GBS only animals. These charcoal. The antibodies against TXB2 and 6-keto-PGF,, were results, combined with our previous finding of transient TX produced in our laboratory (W.R.H.) and have sensitivities of 1 synthase inhibition of TNF, effects (6) , raise questions about pg1O.l-mL sample at a dilution of 1:100 000 and 10 pg1O.l-mL whether PTF can act as a competitive inhibitor of TX and sample at a dilution of 1:6000, respectively (17, 18) . Values whether PTF can alter TNF,-induced pulmonary vasoconstric-below the level of sensitivity were considered to be equal to the tion once the cytokine is released into the pulmonary circulation. sensitivity limit of the assay.
To study possible mechanisms of action of PTF, we tested the Experimental protocol. The methods and experimental protoeffects of PTF infusion in neonatal piglets simultaneously infused cols for these studies were approved by the Animal Care Comwith the TX mimetic U46, 6 19 and in separate animals infused mittee of the University of Washington. with rhTNF,. We investigated the effects of these infusions on Animals were randomized into three groups. Group 1 animals pulmonary and systemic hemodynamic indices, respiratory gas ( n = 6) received a total dose of 200 pg/kg TNF, (9.8 x lo6 U/ exchange, and arachidonate production. mg) infused i.v. at a constant rate into a peripheral vein over 30 min. They also received a bolus of 20 mg/kg PTF before the MATERIALS AND METHODS TNF, infusion followed immediately by a continuous infusion of 20 mg/kg/h PTF for the 2 h of the experimental protocol. Animal preparation. Healthy mixed-strain piglets aged 10-29 Thirteen animals (group 2) received T N E at the same dose at d were prepared as previously described (6) . Each animal was the same infusion rates as the animals in group 1. They also anesthetized with pentobarbital, paralyzed with pancuronium, received 0.9% saline at the same infusion rate as the PTF infusion and mechanically ventilated via a tracheostomy. The animals into the TNF, + PTF-treated animals. Group 3 animals received had pulmonary arterial, systemic arterial, and peripheral venous PTF in the same dosage as group 1 and also received a 30-min catheters inserted. Animals were maintained at a core tempera-infusion of U46619 (0.15 ~g/kg/min) beginning just after the ture of 38.0-38.5"C using overhead heating lamps. Animals PTF bolus. After the 2-h PTF infusion was completed and a new received inflations of twice normal tidal volume before each data baseline was established, a repeat 30-min infusion of U46,6 19 sampling time to minimize atelectasis. Ten mL/kg of 0.9% saline was administered to this group of animals to assess the pulmowere administered to each animal after onset of anesthesia before nary hypertensive response to U46,6 19 without concomitant initiation of the experimental protocol to assure adequate intra-infusion of PTF. vascular volume.
Pulmonary and systemic pressures. were measured continu-TNF, preparation. rhTNF,, derived from Escherichia coli, was ously in all animals. bkasurements of QP, hernodynamic indices, kindly supplied as a gift from Knoll Pharmaceutical Company respiratory gas exchange, and arachidonic acid metabolite levels (Whippany, NJ). The material was supplied as a lyophilized were made at baseline, just before onset of either the TNF,, powder; each glass vial contained 0.98 mg rhTNF, (sp act 9.8 x U46,619, or TNF, plus PTF.infusion, and at 15 (hernodynamics lo6 U/mg). The vials were kept frozen (-70°C) until the day of only), 30,60, and 120 min. Qp was measured at least in triplicate each experiment. The material was reconstituted to 100 pg/mL using the thermodilution technique (Edwards 9520A cardiac with sterile water containing 0.5 g/100 mL human serum albu-output computer; Edwards Laboratories, Santa Ana, CA), and min. Only glass syringes were used for reconstitution and admin-the results were averaged. istration, because rhTNF, adheres less to glass than to plastic.
Two additional animals received a bolus of 20 mg/kg and a Six of the 13 animals receiving TNF, alone received TNF, from continuous infusion of 40 mg/kg/h of PTF during TNF, infusion one batch; the other seven animals in the TNF, alone group and to determine the effects of a higher dosage. Because there was no the six animals receiving TNF, and PTF had their TNF, obtained effect on PVR different from that found at the lower dose and a from a separately supplied batch. Significant contamination of further decline in mean systemic arterial Pressure to 4 kPa (30 the TNF, preparation with endotoxin was ruled out as previously mm Hg), this higher dosage was not used in the main study. We described (6) .
have previously established that the use of anesthesia in similarly PTFpreparation. Intravenous PTF (Trent-1; Hoechst-Roussel instrumented piglets for 6 h of study causes no deterioration in Pharmaceuticals, Somerville, NJ) was prepared fresh each exper-gas exchange or hernodynamic indices (19) . We have also Preimental day. The material was dissolved in sterile normal saline viously shown that animals of similar age and mean weight as and administered by continuous infusion using a glass syringe.
those in the present study treated with the same dose of PTF for U46,619 preparation. The TX mimetic, U46,619, which is 4 h demonstrated no measurable effects (1 1). 9,ll ,dideoxy-l la,ga epoxymethano-prostaglandin (Upjohn Statistical ~T Z~~Y S~S .
One-way analysis of variance Was carried Pharmaceutical Company, Kalamazoo, MI), was supplied as 1 out on the mean data for each group of animals. If intragrou~ mg/mL in methylacetate. Aliquots of 100 ~g were removed, differences were suggested, a paired t test was then camed out to dried, and resuspended in 95% ethanol and stored at -20°C. demonstrate significant differences compared with baseline in Before each experiment, an aliquot was removed, thawed, and each group-Intergroup comparisons were made using the uncombined in normal saline. This solution was administered at a paired t test. Significance Was assumed with a p value (0.05. dose of 0.15 pg/kg/min. Data are presented as mean + SD.
Arachidonic acid metabolite assay. RIA was performed on arterial plasma for measurement of TXB2, the nonenzymatically RESULTS derived breakdown product of TXA,, and 6-keto-PGF,,, the stable metabolite of PGG. The details of the methodology used Baseline comparisons. The three groups of animals were well in our laboratory have been previously published (6, 16) . At each matched by postnatal age and weight at the time of study (Table  sampling time, a 1.8-mL sample of arterial blood was drawn into 1). There was no difference in mean baseline values for Ppa and 0.2 mL freshly prepared cold inhibitor solution containing in-PVR or mean response between the groups of TNF,-only animals domethacin and sodium EDTA, previously drawn into prechilled that had received the TNF, from the two different batches. Data syringes. Samples were kept in an ice bath until centrifugation from these two subgroups were therefore combined. There was at 15 000 rpm x 15 min at 4°C. Plasma was decanted, frozen, no correlation between animal age and pulmonary pressor reand stored at -70°C until RIA was performed. Samples were sponse to TNF, within the age range examined (data not shown). analyzed in duplicate and the two values averaged.
Pulmonary hemodynamic measurements. Infusion of TNF, No matrix effects due to protein present in control piglet and U46, 6 19 induced an increase in Ppa by 15 min. This increase did not occur in the TNF,-treated animals pretreated with PTF, but did occur in the U46,619-treated animals (Fig. 1) . The inhibition in Ppa increase lasted until 2 h after onset of infusion in the TNF, + PTF group (Fig. 1) . No. group of animals demonstrated a significant decline in mean Qp compared to baseline for each group (Fig. 2) . There was no difference in mean Qp between the groups at any experimental measurement point (Fig.  2) . Calculated PVR was maintained at baseline level in the TNF, + PTF-treated animals until 2 h, when it was significantly elevated above baseline and comparable to that found in the animals treated only with TNF, (Fig. 3) . Effect on pulmonary gas exchange. Each group of animals demonstrated no significant decline from baseline for arterial Po2 and Pv02 at each experimental point, with no intergroup difference between mean values (Table 2 ). There was an insignificant decline in arterial Po2 in all three groups of animals by the end of 2 h. Arterial Pco2 was not different by design at any experimental time point in any of the three groups. The TNF,-only animals showed a decline in Pv02 by 2 h; no decline in Pv02 was noted in the TNF, + PTF or the U46,619 + PTF group of animals. Arterial pH did not change in any group (data not shown).
Arachidonic acid metabolite levels. Data for serial measurements of TXB2 and for 6-keto-PGF,, are shown in Figures 5 and   6 . Administration of TNF,-only, TNF, + PTF, or U46,619 + PTF caused no significant change from baseline in TXB2 levels at any experimental time point. Analysis of the 6-keto-PGFI, data showed that TNF, alone and U46,619 + PTF produced no statistically significant increase compared to baseline measurement, comparable to our previous findings with PTF infusion alone (1 1). However, there was a progressive rise in 6-keto-PGF,, levels in the TNF, + PTF-treated animals, such that mean levels were 12-fold higher than baseline by 2 h (p < 0.05) and 15-fold higher compared to the mean level obtained at the same time in the TNF,-only treated animals ( p < 0.02).
DISCUSSION
The present results demonstrated that the methylxanthine derivative PTF can transiently inhibit the TNF,-induced elevation in Ppa and PVR in neonatal animals. However, by 1.5 h after the end of the TNF, infusion, the TNF, + PTF animals manifested the same increase in PVR despite continuous infusion of PTF as that found in the animals that received a 30-min infusion of TNF, alone, the latter group having an elevated PVR after the end of the TNF, infusion. The increased PVR in both groups of animals at 2 h occurred because of a significant increase in Ppa compared to baseline for each group. In contrast, PTF infusion produced no inhibition of the U46,6 19-induced increase in PVR at 15 or 30 min (Figs. 1-3 ). Intravenous infusion with PTF and TNF, was associated with a significant rise in 6-keto-PGFI, levels by 1 h after onset of infusion, a finding particularly marked by 2 h. The acute inhibition of elevated PVR at 15 min was not due to inhibition of TXB2, inasmuch as there was no elevation of TXB2 in either group. Use of PTF with TNF, was also associated with a significant decline in systemic arterial pressure by 2 h after onset of infusion.
When administered acutely, TNF, induces many characteristics of septic shock, including derangements in cardiovascular, metabolic, hematologic, and inflammatory homeostasis (20,2 1). However, it is unlikely that infusion of a single vasoactive The U46,619 + PTF group showed increased PVR at 15 min and 30 min only compared to baseline. By 2 h, PVR is also elevated vs baseline in the TNF, + PTF group. PVR in the TNF,-treated group is greater than that in the TNF, + PTF group at 15 min. *, p < 0.01 vs baseline; t, p < 0.02 vs TNF, + PTF group. mediator, either TNF, or U46, 6 19 , accurately reproduces all of the complex features of neonatal bacterial sepsis, especially the most clinically relevant later phases. Furthermore, the effects of recombinant TNF, on pulmonary hemodynamics are not consistent between species and perhaps between different ages in the same animal species. Guinea pigs treated with TNF, showed only modest and transient elevation in Ppa (21) . Adult sheep demonstrated a marked but nonsustained pulmonary hypertensive response of rapid onset (10) . In contrast to both these models, the neonatal piglet showed marked elevation in Ppa and PVR at 15 min and again by 2 h after the beginning of the TNF, infusion, a TNF, effect not completely explained by its mediation by TXA2 (6) . The finding of no effect of PTF on U46,6 19 implies that PTF does not competitively inhibit previously formed and circulating TXA2, a finding consistent with our previous results in GBS-induced late pulmonary hypertension (1 1).
TNF+ PTF n
The mechanism of action of TNF, on the systemic and pulmonary vasculature in neonatal animals is unclear. TNF, can act both directly on endothelium and also through other vasoactive mediators (22) . At least some of the acute actions of TNF, may be mediated by products of the action of phospholipase A2 on membrane phospholipids. There is evidence that phospholipase A2 is activated by TNF,, because both TXB2 and platelet activating factor have been shown to be released when neutrophils or monocytes are incubated with TNF, (22, 23) . Further, some of the signs of TNF,-induced shock in rats were prevented when the TNF,-exposed animals were pretreated with cyclooxygenase inhibitors (24), a finding that was not corroborated in mice when TNF, was administered with endotoxin (25) . Stimulation of the endothelial monolayer by TNF, increases its adhesiveness for unstimulated neutrophils. This effect occurs because of increased expression of the adhesion molecules ICAM-1 and ELAM-1, a process requiring several hours (26, 27) . Change in circulating cell-endothelial cell adhesiveness would be associated The methylxanthine derivative PTF may inhibit the action of TNF, through a variety of possible mechanisms. PTF inhibits TNF,-induced changes in neutrophil adherence to endothelial cells (12) and protects in vivo against endotoxin-induced pulmonary vascular injury in both dogs (14) and guinea pigs (28) . PTF reduces alveolar edema formation in rabbit lungs injured by repeated saline lavage (29) . These changes may be induced by PTF by inhibiting or antagonizing the activating effect of TNF, on neutrophils. Our present results indicate that PTF transiently inhibits TNF,-induced pulmonary hypertension. Based on previous work (1 1), we hypothesized that the elevated TNF, levels found during later phases of bacterial-product infusion contributed to pulmonary hypertension. Therefore, the present results are relevant to determining effects of the potential pulmonary vasodilator, PTF, or pulmonary hypertension caused by circulating factors that appear during later phases of sepsis. The PTF failed to maintain a sustained reduction in TNF,-induced increases in PVR. Further, the PTF + TNF, animals showed the associated effect of significant systemic hypotension, which may be induced by increases in the circulating levels of PG12, measured as its breakdown product, 6-keto-PGF,,. The increased synthesis and release of PGI2 found in the present study after combined TNF, + PTF infusion may reflect a preference of neonatal endothelial cells to synthesize vasodilator substances once arachidonate metabolism is activated. PG12 has been shown to sustain Qp to locally hypoxic regions, inhibiting the effects of local hypoxic vasoconstriction (30) , an effect potentially interfering with pulmonary gas exchange. No deterioration in gas exchange was detected in the present study, probably because no significant low VA/Q areas develop with TNF, infusion at the dosage used in the current study (6) . The specific site or sites of pulmonary vasodilation would determine the effect of vasodilation on gas exchange. In rabbit lungs in situ, PTF induces arterial but not venous vasodilation (31) ; arterial vasodilation may be less likely to produce VA/Q mismatching.
Systemic hypotension developed in the PTF + TNF,-treated group (Fig. 4) in spite of no significant decline in cardiac output (Fig. 2) . Consistent with these results is the lack of difference in mean mixed venous Po2 at any experimental time point compared to baseline in the TNF, + PTF-treated group (Table 2) . A modest decline in Pv02 was detected in the TNF,-only animals by 2 h. The absence of metabolic acidosis in the TNF, + PTF group suggests maintenance of adequate tissue perfusion during the duration of the protocol.
The dosages of TNF, and U46,6 19 used in the present study were chosen to produce a rapid and sustained elevation in Ppa and PVR without systemic hypotension. Both dosages were derived from our previous studies with these compounds (5, 6) and from work with U46,619 performed by others (9) . The dosage of PTF was based on data already published (28), on our own previous study (1 l) , and on our pilot experiments that demonstrated that an infusion rate of PTF of 40 mg/kg/h resulted in greater systemic hypotension than that found at the lower infusion rate.
In summary, PTF can suppress the TNF,-induced increase in PVR, but not the increase induced by U46, 6 19 . However, at the dosage of PTF used, the inhibitory effect is transient, because by 2 h PVR is elevated to levels comparable to those found after TNF, infusion alone. This pulmonary vascular effect is accompanied by significant systemic hypotension and eicosanoid vasodilator generation. Recently, PTF has been proposed for clinical use in septic shock (32) . Our findings should help establish a framework for clinical studies of PTF in pathophysiologic states in neonates presumed or shown to be associated with TNF, excess production.
